Business Wire

The Estée Lauder Companies Announces That Jane Lauder Will Be Named To The New Role of Executive Vice President, Enterprise Marketing and Chief Data Officer

Share

Today, The Estée Lauder Companies (NYSE:EL) announced that Jane Lauder will be named to the new role of Executive Vice President, Enterprise Marketing and Chief Data Officer, effective July 1, 2020. She will report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC). Jane will be succeeded at Clinique by Michelle Freyre, who will join the brand as Senior Vice President, General Manager, effective July 1, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005543/en/

The Estée Lauder Companies Announces That Jane Lauder Will Be Named To The New Role of Executive Vice President, Enterprise Marketing and Chief Data Officer (Photo: Business Wire)

The Estée Lauder Companies Announces That Jane Lauder Will Be Named To The New Role of Executive Vice President, Enterprise Marketing and Chief Data Officer (Photo: Business Wire)

As ELC’s first ever Enterprise Marketing and Chief Data Officer, Jane will lead our company-wide strategy to build our data-empowered, digitally-directed priorities to accelerate ELC’s growth. By optimizing our vast and valuable data and integrating the company’s analytic capabilities the goal is to drive breakthrough marketing and creative.

“We are focused on delivering the very best, high-quality products that leverage consumer insights from our enhanced data analytics, and I am confident that Jane is the right person to lead this important area of the business,” said Mr. Freda. “As Global Brand President of Clinique and leader of ELC’s enterprise-wide efforts to combine data-driven insights with creativity, she has successfully leveraged data and analytics capabilities to drive strong long-term growth at both the brand and enterprise level. Jane’s unique combination of understanding high-touch consumer experiences, and data analytics and insights, will further strengthen our innovative product offerings and experiences for our consumers globally. I look forward to working even more closely with Jane as she takes on this new role.”

Jane has over two decades of beauty industry experience, including more than 23 years at The Estée Lauder Companies. As Global Brand President of Clinique, she led the transformation of brand strategy, distribution, product innovation and consumer reach, positioning the brand for strong long-term growth. Under Jane’s leadership, Clinique fundamentally shifted nearly one-third of product revenue from low-growth distribution channels to high-growth channels and tripled Clinique’s online business. She also oversaw the development of product innovations including Moisture Surge™ 72-Hour Auto-Replenishing Hydrator and Clinique iD™ and technology innovations with Clinique Clinical Reality™ to strengthen the brand’s skincare position in clinical efficacy and high-touch services and personalization. Clinique’s market share gains in recent months across its core markets are a testament to the rebuilding of the brand.

Jane also leads ELC’s enterprise-wide transformation program focused on combining data and analytics capabilities with creativity to power ELC’s business and digital agenda. In her new role she will continue to drive this competency across the company. As a graduate of Stanford University and member of the Board of Directors of Eventbrite, a California-based global ticketing and event technology platform, Jane’s deep ties to Silicon Valley will be leveraged in her new role.

Jane’s organization will include BI&A, Corporate Marketing and Marketing and Consumer Supported Technology, a forward-looking portfolio management approach to data, marketing and consumer-facing technologies. ELC’s Business Insight & Analytics (BI&A) group will play a central role, and will report directly to Jane with a matrix line into Tracey T. Travis, Executive Vice President and Chief Financial Officer. Jane’s leadership will enable BI&A to continue to accelerate the Company’s ability to unlock value across brands, functions, partners and employees.

Jane will lead the global Corporate Marketing function, including the regional Corporate Marketing organizations, Consumer and Product Marketing Insights, Global Consumer Care and Marketing Planning and A&P effectiveness. She will enable the facilitation and free flow of data among business units to help these teams to mine, analyze and share strategic insights more effectively. She will also enhance the integration of cross-channel data to drive personalized marketing and true omni-channel activation.

Additionally, Jane and her team will ensure that ELC has access to cutting-edge digital innovations through a more formalized approach to strategic digital partnership management, including breakthrough marketing partnerships with leading organizations such as Facebook and Google. Her team will be scouting and developing relationships with emerging influential platforms and players in the marketing, digital innovation and consumer engagement space.

Finally, Jane will be charged with strategically deepening the company’s investments in Talent Management and Capabilities within the Marketing and Consumer Engagement teams, helping to drive talent development, recruitment and breakthrough learning and education programs, making ELC into a career destination of choice for best-in-class brand building, marketing and consumer engagement talent around the world.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049

Media Relations:
Jill Marvin
(212) 572-4438

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCL Technologies Announces Intent to Acquire Leading Australian IT Solutions Company, DWS Limited21.9.2020 04:47:00 EESTPress release

HCL Technologies, (HCL), a leading global technology company, today announced its intent to acquire DWS Limited (ASX: DWS), a leading Australian IT, business and management consulting group. As the IT industry continues to evolve and the growing demand for digital strategies increases, DWS, with over 700 employees and offices in Melbourne, Sydney, Adelaide, Brisbane, and Canberra, delivers business and technology innovation to large clients across a spectrum of verticals. The DWS Group, with FY20 revenue at A$ 167.9 million, provides a wide range of IT services including Digital Transformation, Application development & support, Program & Project Management and Consulting. The acquisition of DWS will strongly enhance HCL’s contribution to Digital initiatives in Australia and New Zealand while strengthening HCL’s client portfolio across key industries. “We are excited for this expansion of HCL Technologies in Australia and New Zealand and are confident that our combined strengths will f

Janssen Presents Findings from Global, Multi-Centre Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer21.9.2020 02:01:00 EESTPress release

FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) mutations,1 in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib2 in patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.3 Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1), clinical benefit rate, duration of response and the safety profile of amivantamab and lazertinib, in the 91 patients treated with the combination across dose escalation and expansion cohorts.3 The study results were presented at the European Society for Medical Oncology (ESMO) Virtual Con

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom